Cellyan Biotechnology (HKPD) Total Current Liabilities (2024 - 2026)
Cellyan Biotechnology (HKPD) posted quarterly Total Current Liabilities of $3.0 million for Q3 2025, down 16.03% year-over-year from $3.6 million in Q3 2024, and up 3.73% quarter-over-quarter from $2.9 million in Q1 2025.
Cellyan Biotechnology (HKPD) Total Current Liabilities (2024 - 2026) Analysis & Trends
Cellyan Biotechnology (HKPD) has reported Total Current Liabilities for 2 consecutive years, with $3.0 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Total Current Liabilities fell 16.03% year-over-year to $3.0 million; the TTM figure through Sep 2025 stood at $3.0 million (down 16.03% YoY), while the FY2025 annual figure was $2.9 million, down 8.16% from the prior year.
- Total Current Liabilities climbed to $3.0 million in Q3 2025 per HKPD's latest filing, from $2.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $3.6 million in Q3 2024 and bottomed at $2.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 102.09 Bn | 96.93 Bn | 3.69 Bn | 70.36 Bn |
| 2 | Cencora | 61.70 Bn | 58.89 Bn | 3.61 Bn | 59.20 Bn |
| 3 | Cardinal Health | 54.26 Bn | 49.41 Bn | 2.56 Bn | 43.90 Bn |
| 4 | Henry Schein | 10.06 Bn | 9.90 Bn | 1.10 Bn | 3.49 Bn |
| 5 | Akso Health | 820.26 Mn | 820.04 Mn | - | 8.71 Mn |
| 6 | Edap Tms | 156.78 Mn | 135.24 Mn | 7.34 Mn | 36.85 Mn |
| 7 | Accendra Health | 94.33 Mn | 86.68 Mn | 263.41 Mn | 666.22 Mn |
| 8 | 111 | 30.87 Mn | 109.39 Mn | 18.18 Mn | 249.09 Mn |
| 9 | Cosmos Health | 13.37 Mn | 10.92 Mn | 1.51 Mn | 34.84 Mn |
| 10 | Cellyan Biotechnology | 6.79 Mn | 6.56 Mn | - | 3.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.20 Mn |
| Sep 30, 2025 | 3.03 Mn |
| Mar 31, 2025 | 2.92 Mn |
| Sep 30, 2024 | 3.60 Mn |
| Mar 31, 2024 | 3.18 Mn |